Journal Home
Search for

Volume 53, Issue 4, Pages 854-861 (15 July 2002)


View previous. 8 of 43 View next.

Expression of hypoxia-inducible factor-1α in cervical carcinomas: correlation with tumor oxygenation

Hans Kristian Haugland, M.D., Ph.D., Vojislav Vukovic, M.D., Ph.D., Melania Pintilie, M.Sc., Anthony W Fyles, M.D., Michael Milosevic, M.D., Richard P Hill, Ph.D., David W Hedley, M.D.Corresponding Author Information§email address

Received 8 October 2001; received in revised form 4 February 2002; accepted 27 February 2002.

Abstract 

To investigate the relations between hypoxia-inducible factor-1 (HIF-1), tumor oxygenation, and clinical correlates in patients with locally advanced carcinoma of the uterine cervix.

Biopsies from 42 patients with invasive cervical carcinoma and previous polarographic O2 measurements were assessed for the expression of HIF-1α using digitized microscopic imaging and analysis.

The HIF-1α expression levels ranged from <0.1% to 10.7% of the total tumor area; the positive staining was localized exclusively to the nuclei. Three distinct arrangement patterns of HIF-1α-positive cells in relation to blood vessels were identified using spatial image mapping: (1) most HIF-1α-positive cells were located within the typical oxygen diffusion distance in tissue (≤150 μm to the nearest blood vessel); (2) most HIF-1α-positive cells were located in the vicinity (≤60 μm) of the blood vessels; and (3) no apparent spatial relationship was found between HIF-1α-positive cells and blood vessels. A statistically significant association was found between HIF-1α expression and tumor oxygenation (Spearman correlation coefficient = 0.4, p <0.01), as determined with the Eppendorf pO2 histograph. No correlation was found between the level of HIF-1α expression and patient outcome, using disease-free survival as the end point.

Our results suggest that HIF-1α expression may represent a useful biologic marker for hypoxia in uterine cervical cancer.

 Department of Medical Biophysics, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada

 Department of Biostatistics, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada

 Department of Radiation Oncology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada

§ Department of Medical Oncology and Hematology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada

 Department of Oncologic Pathology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada

Corresponding Author InformationReprint requests to: David W. Hedley, M.D., Department of Medical Biophysics, Ontario Cancer Institute/Princess Margaret Hospital, 610 University Ave., Toronto, Ontario M5G 2M9 Canada. Tel: 416-946-2262; Fax: 416-946-2984

 Supported by the National Cancer Institute of Canada, using funds raised by the Terry Fox run.

PII: S0360-3016(02)02815-8


View previous. 8 of 43 View next.